gefitinib has been researched along with stilbenes in 9 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (stilbenes) | Trials (stilbenes) | Recent Studies (post-2010) (stilbenes) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 13,935 | 245 | 7,836 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cavanaugh, SX; Hammond, LA; Thomas, CR | 1 |
| Grubbs, CJ; Juliana, MM; Lubet, RA; Steele, VE | 1 |
| Castillo-Pichardo, L; Dharmawardhane, SF | 1 |
| Baskaran, S; Forsberg Nilsson, K; Gerlee, P; Häggblad, M; Hansson, C; Karlsson-Lindahl, L; Kling, T; Lundgren, B; Martens, U; Monsefi, N; Nelander, S; Olsson, M; Schmidt, L; Uhrbom, L; Westermark, B | 1 |
| Ding, J; Fan, XX; He, JX; Huang, J; Huang, M; Jiang, ZB; Kam, RK; Leung, EL; Liu, L; Michelangeli, F; Mujtaba, T; Wong, VK; Xiao, DK; Xu, SW; Xue, WW; Yao, XJ; Zhou, YL | 1 |
| Chen, H; Gao, X; He, W; Li, B; Mei, C; Xu, R; Zhu, Y | 1 |
| Andäng, M; Baskaran, S; Claesson-Welsh, L; Elfineh, L; Forsberg-Nilsson, K; Green, LC; Häggblad, M; Johansson, P; Krona, C; Lönnstedt, I; Lundgren, B; Martens, U; Matuszewski, D; Nelander, S; Padhan, N; Schmidt, L; Sintorn, IM; Uhrbom, L; Wee, S; Westermark, B | 1 |
| Hu, Y; Jin, X; Shi, L; Su, Y; Zhang, C; Zhu, X | 1 |
| Hu, C; Liu, B; Liu, P; Lu, M; Wu, F; Xiong, H | 1 |
9 other study(ies) available for gefitinib and stilbenes
| Article | Year |
|---|---|
An image worth a thousand lives?
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzoquinones; Bibenzyls; Diagnostic Imaging; Down-Regulation; ErbB Receptors; Gefitinib; Heterocyclic Compounds, 1-Ring; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Magnetic Resonance Imaging; Molecular Probe Techniques; Mutation; Neoplasms; Phthalazines; Physiological Phenomena; Positron-Emission Tomography; Protein Binding; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Rifabutin; Stilbenes; Tissue Distribution; Trastuzumab | 2004 |
Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Cyclooxygenase Inhibitors; Disease Models, Animal; Drug Screening Assays, Antitumor; Female; Gefitinib; Naproxen; Quinazolines; Rats; Rats, Inbred F344; Research Design; Resveratrol; Stilbenes; Urinary Bladder Neoplasms | 2010 |
Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer.
Topics: Adenylate Kinase; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase 3; Catechin; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation; Humans; Mice; Mice, SCID; Polyphenols; Proto-Oncogene Proteins c-akt; Quercetin; Quinazolines; Resveratrol; Signal Transduction; Sirolimus; Stilbenes; TOR Serine-Threonine Kinases; Vitis; Xenograft Model Antitumor Assays | 2012 |
Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cell Line, Tumor; Drug Interactions; Gefitinib; Glioblastoma; Humans; Quinazolines; Sertraline; Stilbenes | 2013 |
(Z)3,4,5,4'-trans-tetramethoxystilbene, a new analogue of resveratrol, inhibits gefitinb-resistant non-small cell lung cancer via selectively elevating intracellular calcium level.
Topics: Adenylate Kinase; Antineoplastic Agents; Apoptosis; Calcium; Cell Line, Tumor; Endoplasmic Reticulum Stress; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Quinazolines; Stilbenes | 2015 |
Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cytochrome P-450 CYP1A1; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Quinazolines; Resveratrol; Stilbenes | 2015 |
Case-specific potentiation of glioblastoma drugs by pterostilbene.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Copy Number Variations; Drug Synergism; Female; Gefitinib; Gene Expression Profiling; Gene Knockdown Techniques; Glioblastoma; Humans; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Stilbenes; Transcriptome | 2016 |
A fluorescent light-up aggregation-induced emission probe for screening gefitinib-sensitive non-small cell lung carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Screening Assays, Antitumor; Fluorescent Dyes; Gefitinib; Humans; Lung Neoplasms; Optical Imaging; Peptides; Protein Kinase Inhibitors; Quinazolines; Stilbenes | 2017 |
Trans-3,5,4´-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Heterografts; Humans; MAP Kinase Kinase 1; MicroRNAs; Oncogene Protein v-akt; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Stilbenes | 2019 |